Δ¹²-Prostaglandin D₂

Prostaglandin D₂ (PGD₂) is one of the five primary enzymatic prostaglandins derived directly from PGH₂. PGD₂ is produced abundantly in the CSF by the lipocalin-type PGD synthase, and in the periphery by myeloid cells including mast cells and basophils by a second, hematopoietic-type PGD synthase. PGD₂ is chemically unstable, and its use and analysis is complicated by its short in vivo half-life. Δ¹²-PGD₂ is one of the initial chemical decomposition products of PGD₂. Δ¹²-PGD₂ is an intermediate in the pathway leading to Δ¹²-PGJ₂, which is a cyclopentenone prostaglandin with antimitotic and carcinogenic activities.^1,2 The metabolism of Δ¹²-PGD₂ involves addition of thiol nucleophiles, as is the case with the majority of cyclopentenone prostaglandins.³

WARNING This product is not for human or veterinary use.

1. Fukushima, M. Prostaglandin J₂ - anti-tumor and anti-viral activities and the mechanisms involved. Eicosanoids 3(4), 189-199 (1990).

2. Kato, T., Fukushima, M., Kurozumi, S., et al. Antitumor activity of Δ7-prostaglandin A₁ and Δ12-prostaglandin J₂ in vitro and in vivo. Cancer Res. 46(7), 3538-3542 (1986).

3. Atsmon, J., Sweetman, B.J., Baertschi, S.W., et al. Formation of thiol conjugates of 9-deoxy-Δ9,Δ12(E)-prostaglandin D₂ and Δ12(E)-prostaglandin D₂. Biochemistry 29(15), 3760-3765 (1990).

Schröder, R., Xue, L., Konya, V., et al. PGH₁, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP₂. PLoS One 7(3), e33329 (2012).